Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bluejay Diagnostics (BJDX) Gains from Investment Securities (2022 - 2023)

Bluejay Diagnostics' Gains from Investment Securities history spans 2 years, with the latest figure at -$1244.0 for Q4 2023.

  • For Q4 2023, Gains from Investment Securities rose 90.12% year-over-year to -$1244.0; the TTM value through Dec 2023 reached $42164.0, up 30876.64%, while the annual FY2023 figure was -$6548.0, 118.19% down from the prior year.
  • Gains from Investment Securities for Q4 2023 was -$1244.0 at Bluejay Diagnostics, down from $31361.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $57601.0 in Q1 2023 and bottomed at -$12597.0 in Q4 2022.